Cerebral malaria
diseaseOn this page
Summary
Cerebral malaria (MONDO:0005625) is a disease and 7 clinical trials. Top therapeutic interventions include quinine, mannitol, and sorbitol. A subtype of malaria — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 7
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | cerebral malaria |
| Mondo ID | MONDO:0005625 |
| EFO | EFO:0006857 |
| MeSH | D016779 |
| DOID | DOID:14069 |
| NCIT | C128373 |
| SNOMED CT | 53622003 |
| UMLS | C0024534 |
| MedGen | 44258 |
| GARD | 0024213 |
| Anatomy (UBERON) | UBERON:0000955 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of malaria. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › protozoa infectious disease › malaria › cerebral malaria
Related subtypes (6): Plasmodium ovale malaria, Plasmodium malariae malaria, mixed malaria, blackwater fever, Plasmodium falciparum malaria, Plasmodium vivax malaria
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 7.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 3 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00113854 | PHASE3 | UNKNOWN | Mannitol as Adjunct Therapy for Childhood Cerebral Malaria |
| NCT00124267 | PHASE3 | UNKNOWN | Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria |
| NCT00697164 | PHASE2/PHASE3 | UNKNOWN | Randomized Trial of Erythropoietin During Cerebral Malaria |
| NCT01589289 | PHASE3 | COMPLETED | Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC |
| NCT01660672 | PHASE1/PHASE2 | COMPLETED | Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria |
| NCT01982812 | PHASE2 | COMPLETED | A Safety and Feasibility Study of Enteral LVT vs. Standard of Care for Seizure Control in Pediatric CM |
| NCT06915285 | Not specified | COMPLETED | Automated Detection of Malarial Retinopathy in Patients Diagnosed With Cerebral Malaria |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| QUININE | 4 | 2 |
| MANNITOL | 4 | 1 |
| SORBITOL | 4 | 1 |